Form 8-K PALVELLA THERAPEUTICS, For: Dec 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Palvella Therapeutics (PVLA) PT Raised to $190 at Truist Securities
December 15, 2025 2:14 PM ESTTruist Securities analyst Danielle Brill raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $190.00 (from $105.00) while maintaining a Buy rating.
The analyst comments "We incorporated risk adjusted sales for cutaneous venous malformations (CVM) into our PVLA model which raises our PT to $190 (from... More
Palvella Therapeutics (PVLA) PT Raised to $210 at Cantor Fitzgerald
December 15, 2025 10:09 AM ESTCantor Fitzgerald analyst Josh Schimmer raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $210.00 (from $200.00) while maintaining a Overweight rating.
... More